viewInstem PLC

Instem hails contribution of informatics arm

“We are very excited by the potential here and see this as an increasingly important part of our offering,” said CEO Reason

Instem PLC -

Instem PLC (LON:INS) said it is seeing strong demand for its informatics services with the value of new orders growing by 58% to £840,000.

While the division’s contribution is relatively minor at the moment, it is the pace of expansion that has excited chief executive Phil Reason and the team.

WATCH: Instem PLC reports strong demand for its informatics services

Total order numbers are up by 90% during the first nine months with new business coming from 10 unique clients, compared with six a year earlier.

“We are very excited by the potential here and see this as an increasingly important part of our offering,” said CEO Reason.

Instem specialises in software that streamlines and standardises the regulatory submissions process for early-stage drug development.

Informatics is a natural extension for the company. By processing and storing data it has garnered, the company has been able to develop gene- or drug-specific target safety assessments (TSAs).

TSAs are used to assess unintended adverse consequences of potential treatments before expensive investment is made and, crucially, long before they are administered to people.

Currently, this process is costly, particularly for small and mid-sized firms, which have to outsource it.

Instem’s ‘in silico’ (computer-based) methodology is cheaper than the traditional, lab-based approach and brings with it an element of standardisation lacking currently from the current process.

In the update, the AIM-listed software group said the expansion into informatics was bringing it into contact with customers at an early stage in the drug development process.

“There is growing demand for TSA services, which determine the viability of developing drugs at an early stage, thereby ensuring that companies are able to make decisions early in the development curve and avoid unnecessary spend,” investors were told.

Quick facts: Instem PLC

Price: 481.1 GBX

Market: AIM
Market Cap: £80.22 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...



Instem PLC's Phil Reason says they've been really busy during lockdown and...

Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy'...

1 day, 2 hours ago

2 min read